WGO Graded Evidence: Hepatitis B

Level: Other Reading: 120 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Hepatitis B virus resistance to nucleos(t)ide analogues. Zoulim F, Locarnini S, Gastroenterology. 2009 Nov;137(5):1593-608.e1-2
	Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. You H, Ma H, Liu T, Cong M, Wang P, Ou X, Wang X, Ren J, Li H, Wang B, Jia J, J Viral Hepat. 2009 Dec;16(12):876-82
	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. Nguyen VT, Law MG, Dore GJ, J Viral Hepat. 2009 Mar 13;
	HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V, Filippini P, Hepatology. 2009 Apr;49(4):1090-7
	Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. Nguyen MH, Keeffe EB, J Viral Hepat. 2009 Mar;16(3):149-55
	Epidemiology of hepatocellular carcinoma in Japan. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K, J Gastroenterol. 2009;44 Suppl 19:102-7
	High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH, J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):203-8
	On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, Janssen HL, J Viral Hepat. 2009 Feb;16(2):113-20
	Hepatitis B virus infection. Liaw YF, Chu CM, Lancet. 2009 Feb 14;373(9663):582-92
	Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. Guo X, Jin Y, Qian G, Tu H, J Hepatol. 2008 Nov;49(5):718-25 Cat: Journal Article
	HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ, Am J Gastroenterol. 2008 Sep;103(9):2254-62
	Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. MN Brunelle, AC Jacquard, C Pichoud, D Durantel, S Carrouée-Durantel, JP Villeneuve, C Trépo, F Zoulim, Hepatology. 2005 Jun:1391-8
	Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. M Chen, YG Li, DZ Zhang, ZY Wang, WQ Zeng, XF Shi, Y Guo, SH Guo, H Ren, World J Gastroenterol. 2005 Mar 28:1806-8
	Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Hepatology. 2009 Oct;50(4):1064-71
	Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK, Gastroenterology. 2009 Oct;137(4):1289-300
	Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL, Am J Gastroenterol. 2009 Oct;104(10):2449-57
	The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma. Choi GH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Lee WJ, Han KH, Chon CY, Kim BR, J Gastroenterol Hepatol. 2009 Mar;24(3):391-8
	A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, Sebastiani G, Palù G, Alberti A, Hepatology. 2009 Oct;50(4):1038-44
	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Günthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S, Hepatology. 2009 Oct;50(4):1017-29
	Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, Moreno A, González-Serrano M, Iribarren JA, Ortega E, Miralles P, Mira JA, Pineda JA, Hepatology. 2009 Oct;50(4):1056-63
	Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, Weiss H, Vargas G, Lemon SM, Gastroenterology. 2009 Oct;137(4):1448-58
	Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, Anderson FH, Krahn MD, Am J Gastroenterol. 2009 Oct;104(10):2439-48
	The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. Fang ZL, Sabin CA, Dong BQ, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ, J Hepatol. 2009 Feb;50(2):273-80
	The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH, J Hepatol. 2009 Feb;50(2):281-8
	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL, Gut. 2009 Jan;58(1):111-7
	Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS, J Hepatol. 2009 Jan;50(1):42-8
	Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M, REPENTINA study, Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa, Am J Gastroenterol. 2009 Jan;104(1):57-63
	Cationic polymers that enhance the performance of HbsAg DNA in vivo. GW Bos, T Kanellos, DJ Crommelin, WE Hennink, CR Howard, Vaccine. 2004 Dec 9:460-9
	Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, Wu HY, Liang XS, Zhang P, Zhao JF, Tan XJ, Lu W, Schaefer S, Cao GW, Gut. 2008 Dec;57(12):1713-20
	Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K, Scand J Gastroenterol. 2008;43(7):849-56
	Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ, Gastroenterology. 2008 Jul;135(1):111-21
	MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N, Gastroenterology. 2008 Jul;135(1):257-69
	Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, Crocè LS, Granito A, Tiribelli C, Bellentani S, Am J Gastroenterol. 2008 Sep;103(9):2248-53
	Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation. I Desombere, T Cao, Y Gijbels, G Leroux-Roels, Clin Exp Immunol. 2005 Apr:126-37
	Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. Piroth L, Carrat F, Larrat S, Goderel I, Martha B, Payan C, Lunel-Fabiani F, Bani-Sadr F, Perronne C, Cacoub P, Pol S, Morand P, J Hepatol. 2008 Dec;49(6):892-8
	Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. MA Hernán, SS Jick, MJ Olek, H Jick, Neurology. 2004 Sep 14:838-42
	The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos E, Sivridis E, Papoutselis K, J Hepatol. 2008 Dec;49(6):884-91
	Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ, Hepatology. 2008 Nov;48(5):1451-9
	Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. Sun HY, Ko WC, Tsai JJ, Lee HC, Liu CE, Wong WW, Su SC, Ho MW, Cheng SH, Yang CH, Lin YH, Miao WJ, Sheng WH, Hung CC, Am J Gastroenterol. 2009 Apr;104(4):877-84
	The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. Caldwell S, Park SH, J Gastroenterol. 2009;44 Suppl 19:96-101
	How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. Ong SC, Lim SG, Li SC, J Viral Hepat. 2009 Jan;16(1):53-63
	Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. Raptopoulou M, Papatheodoridis G, Antoniou A, Ketikoglou J, Tzourmakliotis D, Vasiliadis T, Manolaki N, Nikolopoulou G, Manesis E, Pierroutsakos I, J Viral Hepat. 2009 Mar;16(3):195-202
	High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Marschall T, Kretzschmar M, Mangen MJ, Schalm S, Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1214-25
	Prevalence of hepatitis C infection and risk factors in hospitalized diabetic patients: results of a cross-sectional study. Cadranel JF, Di Martino V, Lambrey G, Mourlhon C, Nalet B, Anciaux ML, Richard C, Bigué JP, Barjon JN, Bories C, Barbare JC, Halimi C, Ribière O, Eugène C, Pauwels A, Jeanne S, Donato L, Dumouchel P, Pariente A, Duverlie G, Devergie B, Arlot S, Capron D, Eur J Gastroenterol Hepatol. 2008 Sep;20(9):829-36
	A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting. Sangfelt P, Uhnoo I, Reichard O, Weiland O, Scand J Gastroenterol 2008;43(4):465-72
	A survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countries. TM Chan, J Chapman, CJ Lee, Z Morad, ET Ona, K Park, A Pingle, SA Rizvi, FA Shaheen, V Sumethkul, XD Tang, Y Watarai, Transplant Proc. 2004 Sep:2126-7
	Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. B Duval, V Gîlca, N Boulianne, P De Wals, R Massé, G Trudeau, G De Serres, Pediatr Infect Dis J. 2005 Mar:213-8
	Hepatitis B surface antigen presentation and HLA-DRB1*- lessons from twins and peptide binding studies. A Kruger, P Adams, J Hammer, WO B&oeig;cher, PM Schneider, C Rittner, T Hoehler, Clin Exp Immunol. 2005 May:325-32
	Hepatitis B virus: significance of genotypes. S Schaefer, J Viral Hepat. 2005 Mar:111-24
	Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. F Fabrizi, V Dixit, M Magnini, A Elli, P Martin, Aliment Pharmacol Ther. 2006 Aug 1:497-506
	Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. F Fabrizi, SV Ganeshan, V Dixit, P Martin, Aliment Pharmacol Ther. 2006 Sep 1:789-96
	Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. F Fabrizi, V Dixit, P Martin, Aliment Pharmacol Ther. 2006 Jun 1:1559-66
	Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K, Koga H, Takao Y, Sata M, Dig Dis Sci. 2008 Nov;53(11):2999-3006
	Sexual transmission of hepatitis B. M Atkins, M Nolan, Curr Opin Infect Dis. 2005 Feb:67-72
Supplementary evidence:
	Need to strictly define hepatitis B virus immunotolerant patients to avoid unnecessary liver biopsy. Andreani T, Serfaty L, Poupon R, Chazouilleres O, Gastroenterology. 2008 Dec;135(6):2155-6
	A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) data MR Geier, DA Geier, Clin Exp Rheumatol. 2004 Nov-Dec:749-55
	A promising therapeutic vaccination to suppress hepatitis B virus replication in immunosuppressed patients. M Imawari, J Gastroenterol. 2004 Sep:913-4
	A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. P Van Damme, K Van Herck, Expert Rev Vaccines. 2004 Jun:249-67
	Acceptability of universal hepatitis B vaccination among school pupils and parents. A Hinds, JC Cameron, Commun Dis Public Health. 2004 Dec:278-82
	Acceptance and completion of hepatitis B vaccination among drug users in New York City. DC Ompad, S Galea, Y Wu, CM Fuller, M Latka, B Koblin, D Vlahov, Commun Dis Public Health. 2004 Dec:294-300
	Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. BJ McMahon, DL Bruden, KM Petersen, LR Bulkow, AJ Parkinson, O Nainan, M Khristova, C Zanis, H Peters, HS Margolis, Ann Intern Med. 2005 Mar 1:333-41
	Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. GA Poland, RM Jacobson, N Engl J Med. 2004 Dec 30:2832-8
	Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. CA Siegrist, M Pihlgren, C Tougne, SM Efler, ML Morris, MJ AlAdhami, DW Cameron, CL Cooper, J Heathcote, HL Davis, PH Lambert, Vaccine. 2004 Dec 16:615-22
	Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. RJ Jacobs, GA Gibson, AS Meyerhoff, Infect Control Hosp Epidemiol. 2004 Jul:563-9
	Determining the point of indifference--where costs of selective and universal immunization against hepatitis B are identical, in a cost-minimization exercise. RM Varghese, J Abraham, J James, JM Puliyel, Indian J Gastroenterol. 2004 Jul-Aug:154-6
	Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. JC Aguilar, Y Lobaina, V Muzio, D García, E Pentón, E Iglesias, D Pichardo, D Urquiza, D Rodríguez, D Silva, N Petrovsky, G Guillén, Immunol Cell Biol. 2004 Oct:539-46
	Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. KS Jaganathan, P Singh, D Prabakaran, V Mishra, SP Vyas, J Pharm Pharmacol. 2004 Oct:1243-50
	Does efficient haemodialysis improve the response to hepatitis B virus vaccination? V Kovaci., M Sain, V Vukman, Lijec Vjesn. 2004 May-Jun:133-7
	Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the scho L Salleras, A Dominguez, M Bruguera, N Cardeñosa, J Batalla, G Carmona, E Navas, JL Taberner, Vaccine. 2005 Mar 18:2181-4
	Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. F Fagnani, C Le Fur, I Durand, M Gibergy, Eur J Health Econ. 2004 Jun:143-9
	Effectiveness of hepatitis B vaccination in children of chronic hepatitis B mothers. P Adibi, R Ghassemian, SM Alavian, M Ranjbar, AH Mohammadalizadeh, F Nematizadeh, M Mamani, M Rezazadeh, F Keramat, A Ardalan, A Esmaeili, MR Zali, Saudi Med J. 2004 Oct:1414-8
	Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B. M Helvaci, A Kizilgunesler, E Kasirga, E Ozbal, M Kuzu, G Sozen, J Gastroenterol Hepatol. 2004 Jul:785-91
	Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. E Navas, L Salleras, R Gisbert, A Dominguez, M Bruguera, G Rodríguez, N Galí, A Prat, Vaccine. 2005 Mar 18:2185-9
	Evolution of strategy and coverage rates for hepatitis B vaccination in France, a country with low endemicity F Denis, V Abitbol, A Aufrère, Med Mal Infect. 2004 Apr:149-58
	Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. RS Garfein, WA Bower, CM Loney, YJ Hutin, GL Xia, J Jawanda, AV Groom, OV Nainan, JS Murphy, BP Bell, Hepatology. 2004 Oct:865-73
	Factors associated with receiving hepatitis B vaccination among high-risk adults in the United States: an analysis of the National Health Interview Survey, 2000. N Jain, H Yusuf, PM Wortley, GL Euler, S Walton, S Stokley, Fam Med. 2004 Jul-Aug:480-6
	Genetic regulation of immune responses to vaccines in early life. MJ Newport, T Goetghebuer, HA Weiss, H Whittle, CA Siegrist, A Marchant, MRC Gambia Twin Study Group, Genes Immun. 2004 Mar:122-9
	HBV vaccination should be performed in service centres for drug users: an Italian experience. G Quaglio, F Lugoboni, P Mezzelani, J Public Health (Oxf). 2004 Sep:320
	Hepatitis B and C. Risk of transmission from infected health care workers to patients WH Gerlich, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Apr:369-78
	Hepatitis B and hepatitis C viruses in liver transplantation. MP Curry, Transplantation. 2004 Oct 15:955-63
	Hepatitis B mother--to--child transmission. S Ranger-Rogez, F Denis, Expert Rev Anti Infect Ther. 2004 Feb:133-45
	Hepatitis B vaccination associated with higher female than male mortality in Guinea-bissau: an observational study. ML Garly, H Jensen, CL Martins, C Balé, MA Baldé, IM Lisse, P Aaby, Pediatr Infect Dis J. 2004 Dec:1086-92
	Hepatitis B vaccination coverage in Belgian health care workers. R Vranckx, P Jacques, A De Schrijver, G Moens, Infection. 2004 Oct:278-81
	Hepatitis B vaccination for patients with chronic renal failure. RJ Schroth, CA Hitchon, J Uhanova, A Noreddin, SP Taback, ME Moffatt, JM Zacharias, Cochrane Database Syst Rev. 2004:CD003775
	Hepatitis B vaccination in France: vaccination coverage in 2002 F Denis, Bull Acad Natl Med. 2004:115-23
	Hepatitis B vaccines. AS Yu, RC Cheung, EB Keeffe, Clin Liver Dis. 2004 May:283-300
	Hepatitis B vaccines. [No Authors Listed], Wkly Epidemiol Rec. 2004 Jul 9:255-63
	Hepatitis B: epidemiology and natural history. TT Tran, P Martin, Clin Liver Dis. 2004 May:255-66
	High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. MJ Ghabouli, AH Sabouri, N Shoeibi, SN Bajestan, H Baradaran, Eur J Epidemiol. 2004:871-5
	Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins. WG Hu, J Wei, HC Xia, XX Yang, F Li, GD Li, Y Wang, ZC Zhang, World J Gastroenterol. 2005 Apr 14:2088-94
	Immunogenicity and safety of hepatitis B vaccine (Shanvac-B) using a novel pre-filled single use injection device Uniject in Indian subjects. N Joshi, A Kumar, MB Raghu, S Bhave, R Arulprakash, P Bhusari, R Rao, Indian J Med Sci. 2004 Nov:472-7
	Incidence of viral hepatitis B and vaccination in the Arkhangelsk region, Russian Federation. A Tulisov, R Buzinov, T Gordienko, Int J Circumpolar Health. 2004:205-8
	Lichen planus induced by hepatitis B vaccination: a new case and review of the literature. D Calista, M Morri, Int J Dermatol. 2004 Aug:562-4
	Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. EH Boxall, J A Sira, N El-Shuhkri, DA Kelly, J Infect Dis. 2004 Oct 1:1264-9
	Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years. DS Chen, Ann Intern Med. 2005 Mar 1:384-5
	Management of hepatitis B in children. A Broderick, MM Jonas, Clin Liver Dis. 2004 May:387-401
	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. A Godkin, M Davenport, AV Hill, Hepatology. 2005 Jun:1383-90
	Much gained by integrating contact tracing and vaccination in the hepatitis B antenatal screening program in Amsterdam, 1992-1999. JE van Steenbergen, D Baayen, PG Peerbooms, RA Coutinho, A Van Den Hoek, J Hepatol. 2004 Jun:979-85
	Practical difficulties in the management of hepatitis B in the Asia-Pacific region. R Mohamed, P Desmond, DJ Suh, D Amarapurkar, E Gane, Y Guangbi, JL Hou, W Jafri, CL Lai, CH Lee, SD Lee, SG Lim, R Guan, PH Phiet, T Piratvisuth, J Sollano, JC Wu, J Gastroenterol Hepatol. 2004 Sep:958-69
	Preventing and treating hepatitis B infection. R Aggarwal, P Ranjan, BMJ. 2004 Nov 6:1080-6
	Preventing and treating hepatitis B infection: immunisation is most important strategy to control hepatitis B. OD Mansoor, N Wilson, BMJ. 2005 Jan 22:197-8
	Prevention of hepatitis B in juveniles. Effect of a medical health education lesson in school C Layer, G Gille, C Klapp, U Ravens-Sieberer, Med Klin (Munich). 2004 Dec 15:703-7
	Prisoners' attitudes toward Hepatitis B vaccination. S Vallabhaneni, GE Macalino, SE Reinert, B Schwartzapfel, FA Wolf, JD Rich, Prev Med. 2004 Jun:828-33
	Protection of children born to hepatitis-B-infected mothers HJ Boot, PE Vermeer-de Bondt, TG Kimman, Ned Tijdschr Geneeskd. 2004 Sep 11:1816-8
	Recombivax-HB: perspectives past, present and future. C Venters, W Graham, W Cassidy, Expert Rev Vaccines. 2004 Apr:119-29
	Review article: hepatitis vaccination in patients with chronic liver disease. G Reiss, EB Keeffe, Aliment Pharmacol Ther. 2004 Apr 1:715-27
	Routine infant hepatitis B vaccination recommendations. SG Humiston, GS Marshall, Pediatr Ann. 2004 Aug:515-22
	Seroprevalence of hepatitis B and C in the Western Brazilian Amazon region (Rio Branco, Acre): a pilot study carried out during a hepatitis B vaccination program. J Tavares-Neto, D Almeida, MC Soares, R Uchoa, S Viana, R Darub, E Farias, G Rocha, L Vitvitski, R Paraná, Braz J Infect Dis. 2004 Apr:133-9
	Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. HY Hsu, MH Chang, YH Ni, HL Chen, Gut. 2004 Oct:1499-503
	Systemic adverse effects of hepatitis B vaccines are rare. [No Authors Listed], Prescrire Int. 2004 Dec:218-23
	The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. IH Kara, ME Yilmaz, A Suner, AK Kadiroglu, B Isikoglu, Vaccine. 2004 Sep 28:3963-7
	The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. L Goncalves, B Albarran, S Salmen, L Borges, H Fields, H Montes, A Soyano, Y Diaz, L Berrueta, Virology. 2004 Aug 15:20-8
	The risk of contracting hepatitis A or hepatitis B run by visitors to the Mediterranean and Eastern Europe S Pr&oeig;ll, HD Nothdurft, MMW Fortschr Med. 2004 May 13:51-4
	To vaccinate or not to vaccinate--that is the question: why are some mothers opposed to giving their infants hepatitis B vaccine? A Maayan-Metzger, P Kedem-Friedrich, J Kuint, Vaccine. 2005 Mar 14:1941-8
	Vaccinated but not immunized: protection against hepatitis B in medical staff in the developing world. JS Sorabjee, R Garje, J Hosp Infect. 2004 Oct:164-5
	Vaccination against hepatitis B virus: ANAES and INSERM experts take a view F Degos, Gastroenterol Clin Biol. 2004 Jan:50-3
	Vaccine coverage with hepatitis B and other vaccines in the Colombian Amazon: do health worker knowledge and perception influence coverage? F de la Hoz, L Perez, JG Wheeler, M de Neira, AJ Hall, Trop Med Int Health. 2005 Apr:322-9
	Vaccines for neonatal viral infections: hepatitis B vaccine. FT Cutts, AJ Hall, Expert Rev Vaccines. 2004 Aug:349-52
	Virology, epidemiology and transmission mechanisms of hepatitis B virus D Moreno, F Alegre, N García-González, An Sist Sanit Navar. 2004:7-16